Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 331

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 331
---
  |     |        | 11.0x |     |      | 16.1x |
| High                                               |     |                |           |     |                |          |   |     |                |          |   |     |       | 21.7x |     |        | 54.4x |     |      | 69.3x |
| Low                                                |     |                |           |     |                |          |   |     |                |          |   |     |       | 0.4x  |     |        | 4.2x  |     |      | 7.2x  |

Notes:

| (1) | Values in millions of US Dollars. |

| (2) | Source: S&P Capital IQ. |

To determine a reasonable valuation for the drug indication, CB Capital had to craft two additional assumptions:

WACC Analysis:

| Cost of Capital Assumptions |     |       |   |     |                                                                                               |
| Risk-free rate              |     |  3.85 | % |     | Source: 10-Year Treasury Rate as of 08-14-24.                                                 |
| Equity risk premium (ERP)   |     |  5.00 | % |     | Source: Kroll Recommended US Equity Risk Premium Effective 06-05-24.                          |
| Small company risk premium  |     |  3.00 | % |     | Source: Ibbotsons Small Cap Premium, Using DECA market cap as of 08-14-24 of 81.4 MM (CapIQ). |
| Unsystematic risk factor    |     | 13.04 | % |     | Source: Journal of Risk and Financial Management.                                             |
| Cost of debt                |     | 13.60 | % |     | Source: US CCC rated corporate bonds effective yield as of 08-14-24.                          |

187

Comparable Company Information

| Comparable Company Names                           |     | Common        
 Stock Price   
 per Share     
 (08-14-24)($) |        |     | Number of   
 Shares      
 Outstanding |       |     | LTM       
 Preferred 
 Equity($) |   |     | Market Value 
 of Equity($) |         |
| Amgen Inc. (NasdaqGS:AMGN)                         |     |               | 323.45 |     |             |   537 |     |           | — |     |